The PennZone

  • Home
  • Business
  • Health
  • Non-profit
  • Technology
  • Services
  • Sports
  • Books
  • Entertainment

MYONEX ANNOUNCES ACQUISITION OF SAVEWAY COMPOUNDING PHARMACY TO EXPAND ITS CLINICAL TRIAL SERVICES ACROSS THE US USA - English USA - español USA - English
The PennZone/10266682

Trending...
  • UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels
  • CCHR Florida Joins Global Call to Ban Electroshock Treatment, Citing New Evidence of Widespread Patient Harm
  • BoxingRx Announces Full Gym Renovation Ahead of New Ownership's One-Year Anniversary
HORSHAM, Pa., April 9, 2024 ~ Myonex, a leading global clinical trial supply company, has recently announced the completion of its acquisition of SaveWay Compounding Pharmacy in Newark, Delaware. The pharmacy will now operate as SaveWay Compounding Pharmacy, a Myonex company.

This strategic move by Myonex is part of their ongoing efforts to support clinical trial sponsors' trial designs with direct-to-patient (DTP) and home healthcare provider (HHP) capabilities. With this acquisition, Myonex aims to provide wider patient access across the entire United States and support patients in obtaining the necessary trial medication and equipment.

According to James Lovett, Chief Executive Officer at Myonex, "SaveWay's pharmacy capabilities complement and extend our existing clinical supplies solutions within the US. SaveWay will provide additional access for drug sourcing and direct-to-patient options across all 50 states for our clinical packaging and labeling and ancillary supply services." This will also complement Myonex's market-leading CTRx™ to offer a full suite of prescription-based supply options for both investigational medicinal product (IMP) and commercial drug access throughout the US. These added capabilities will enable Myonex to better serve their clients' needs and facilitate decentralized clinical trials (DCT) and hybrid studies.

More on The PennZone
  • Milwaukee Job Corps Center Hosts Alumni Day, Calls Alumni to Action on Open Enrollment Campaign
  • Ezra Wohlgelernter Installed Philadelphia Bar Association Chancellor
  • Power Couple Launches "Happy Habits Events" After Best of Philly Win, Pandemic Loss, and Setbacks
  • Golden Paper Identifies Global Growth in Packaging Papers and Upgrades Its High-End Production Capacity
  • Champagne, Caviar Bumps & Pole Performances — Welcome the New Year Early with HandPicked Social Club

The acquisition also presents an opportunity for SaveWay to expand into the realm of clinical trials and accelerate the growth of their direct-to-patient services. Pradeep Chilakapati, RPh, Managing Partner and Pharmacist at SaveWay, expressed excitement about this partnership: "We welcome the opportunity to be part of an experienced clinical trial supply company with its roots in pharmacy. Myonex understands how we work and what we can offer to support today's trends in clinical trials."

This recent acquisition announcement comes on the heels of another significant acquisition by Myonex – that of Creapharm – further solidifying their commitment to providing faster, more flexible, and reliable services to their clients while improving the clinical trial patient experience. With these acquisitions, Myonex now boasts one of the most diverse clinical trial supply service offerings globally.

Myonex was exclusively advised by Crosstree as its financial advisor and Troutman Pepper as its legal advisor in this acquisition of SaveWay. This partnership is expected to bring about significant growth and success for both companies in the clinical trial supply industry.
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio
  • Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
  • VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
  • Children Rising Appoints Marshelle A. Wilburn as New Executive Director
  • Nonprofit Operations' First-Of-Its-Kind Job Portal Empowers Nonprofit Job Seekers
  • Fairmint CEO Joris Delanoue Elected General Director of the Canton Foundation
  • Sleep Basil Mattress Co.'s Debuts New Home Page Showcasing Performance Sleep Solutions for Active Denver Lifestyles
  • Bent Danholm Joins The American Dream TV as Central Florida Host
  • The Nature of Miracles Celebrates 20th Anniversary Third Edition Published by DreamMakers Enterprises LLC
  • Artificial Intelligence Leader Releases Children's Book on Veterans Day
  • KDG Recognized on the Clutch 1000 List for 2025
  • SNS Research Group has published its flagship report, "Dermatological Drugs Market: 2025–2035"
  • Felicia Allen Hits #1 Posthumously with "Christmas Means Worship"
  • CCHR Documentary Probes Growing Evidence Linking Psychiatric Drugs to Violence
  • The Rise of Experience Gifting: Families Choosing Memories Over More Stuff This Christmas
  • Pittsburgh Family Law Firm Pollock Begg Elevates Two Attorneys to Partner Ranks
  • Innovu Launches Auto Analysis, an AI Feature That Explains Healthcare Data in Plain Language
  • Tokenized Real-World Assets: Iguabit Brings Institutional Investment Opportunities to Brazil
  • MEX Finance meluncurkan platform keuangan berbasis riset yang berfokus pada data, logika, dan efisiensi pengambilan keputusan investasi
  • From MelaMed Wellness to Calmly Rooted: A New Chapter in Functional Wellness

Popular on PennZone

  • Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders - 902
  • BumblebeeSmart Introduces Rounded Busy Board Set for Preschoolers - 263
  • Light Her Way Launches New Cohort of Board of AdviseHERS to Prepare Women for Board-Ready Leadership - 114
  • Dispelling Holiday Suicide Myth: CDC Data Shows Suicide Rates Lowest in December; International Survivors of Suicide Day Emphasizes Need for Action
  • Cut Costs & Boost Profits with the First Major Upgrade in 30 YEARS Replacing Rotary Lasers and Historic Clear Tube Altimeter Bubbles
  • Cyntexa Announces Updates to ChargeOn on Salesforce AppExchange
  • Discover Elevated Living - Preview the Stunning New Townhome Collection
  • Lineus Medical Receives Patent for SafeBreak® Vascular Generation 2
  • Free At Last Bail Bonds Gives Back Through Major Holiday Food Distribution Efforts Across Metro Atlanta
  • NorthSky Celebrates One-Year Anniversary

Similar on PennZone

  • AI-Driven Cybersecurity Leader Gains Industry Recognition, Secures $6M Institutional Investment, Builds Momentum Toward $16M Annual Run-Rate Revenue
  • Allegiant Management Group Named 2025 Market Leader in Orlando by PropertyManagement.com
  • LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio
  • Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
  • KDG Recognized on the Clutch 1000 List for 2025
  • New Angles US Group Founder Alexander Harrington Receives Top U.S. Corporate Training Honor and Leads Asia-Pacific Engagements in Taiwan
  • Contracting Resources Group Receives 2025 HIRE Vets Platinum Medallion Award from the U.S. Department of Labor
  • EnergyStrat Launches Global LNG Risk Outlook 2025–2030
  • Strong Revenue Gains, Accelerating Growth, Strategic Hospital Expansion & Uplisting Advancements: Cardiff Lexington Corporation (Stock Symbol: CDIX)
  • Rigani Press Announces Breakthrough Book for Health IT and Medical Leaders to Forge the Road to Responsible AI
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us